good question and that could be discussed at the AGM.
I think some of the ADO scientists have been located in offshore offices to speed up processes etc so I am pretty sure there is some very active testing going on but how many - I don't know.
I do know that a lot of companies stuff up the process and say it doesn't work so ADO need to hold ther hand a little and when they do the results appear so there is a pretty extensive learning process.
The problem for ADO an it's ASX disclosure requirements are manylayered - first there are the confidentially issues with the end client - but what if the SP double on the back of ADO announcing tat a product has gone t FDA approval using M&G and then t gets rejected and teh SP halves - was that keeping shareholders better informed?
I personally don't believe the ANY product has gone to any approval stage with M&G in it - I think that the approach of ADO has been to 'give it away' for virtually nothing for people to play with but that a reseach agreement would need to be signed for an application like that. I would think all royalties etc would be agreed and ADO would be earning research revenue in a collaboration agreement.
It could be the other way aroud - many here are more savvy on these types of things than I and I have never discussed details like that with Geoff.
ADO Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)